You're viewing an archived version of this project. Please visit the new Big Give site to find current fundraising campaigns.

Project information

Molecular Imaging Research Centre - Phase 2b

To provide the UK's first fully comprehensive PET-CT scanning service, bringing together the needs of the local population, microfluidic technology and GE Healthcare's small cyclotron technology to put the sub-region in a prominent international position in regard to PET-CT research and development.

August 2018 - August 2019

Charity information: Daisy Appeal (Hull And East Yorkshire Medical Research Centre)

Daisy Appeal (Hull And East Yorkshire Medical Research Centre) logo
  • Need


    The charity is trying to improve accuracy and detection rates for cancer, heart disease and dementia in Hull, East Yorkshire and North Lincolnshire; cancer is a leading cause of death in the area as is heart disease. Dementia is an increasingly common disease with sufferers and their families having to face the consequences every day of their lives.


    Cancer survival can be improved by earlier and more accurate detection as can heart disease with patients being able to change their lifestyles and improve their quality of life. Earlier detection of dementia will allow recognition and treatment, making the final years of life more bearable for both the sufferer and their families.

  • Aims

    Aim 1

    To build and equip a radiochemistry and cyclotron unit to produce our own radioactive tracers


    » Apply for tailored grant funding specific to the project
    » Organise various fundraising activities, both public and corporate, to raise the funding required.

    What success will look like

    The new facility will provide the opportunity for patients to receive more personalised treatment leading to earlier diagnosis and giving them a better chance of survival.

  • Impact


    The new facility will give researchers the opportunity to develop new radiotracers for the diagnosis and treatment of cancer, heart disease and dementia. These new radiotracers can be used in the scanning process for better outcomes in these diseases for all patients and hopefully better survival rates.


    The fundraising target for this project is immense and does pose a risk for the charity, however, he Trustees have put in place contingencies to ensure that the project will go ahead even if there is a fundraising deficit.


    We will update our web site, social media and make contact when possible with personal donors if we have their details.

  • Budget

    Budget - Project Cost: £2,100,000

    Loading graph....
      Amount Heading Description
      £70,000 Design Fees Fees for architects etc.
      £1,000,000 Equipment Costs Cyclotron and associated equipment
      £1,030,000 Construction Design and build costs
  • Background


    The charity is based at Castle Hill Hospital in East Yorkshire which also accommodates the regional cancer and cardiothoracic centres, but serves the population of Hull, East Riding of Yorkshire and North Lincolnshire. The area is very large and diverse with high incidences of cancer and heart disease. Once the facility is fully functional patients from a wider geographical area will have access to its services.


    Patients living locally and in the areas mentioned above will benefit from the project as working closely with the local NHS, the University of Hull and Alliance Medical Ltd the charity aims to play a leading role in clinically relevant PET-CT research over the next two decades. The charity's intention is to show that the technology can be brought to the individual patient, quickly and effectively, rather than the other way round.

  • Why Us?

    Why Us?

    The charity has locally available expertise and opportunities to provide a fully integrated lab-to-bedside approach to the development of new radiotracers for PET-CT scanning. The GE cyclotron, which the charity is purchasing, not only produces the F18 isotope but also C11. This isotope will provide the opportunity to develop a whole new group of radiotracers to allow the accurate imaging of non-cancerous disease processes such as certain cardiac conditions and neurological diseases.

    Read more about the Charity running this project.


    Professor Steve Archibald

    Steve is Professor of Molecular Imaging Chemistry at the University of Hull whose research interests include radiopharmaceutical imaging.

    Professor Nick Stafford

    Chairman of the charity's Trustees and the driving force behind the project.

    Mr David Haire

    David is the Project Director providing a vital link between the charity and the local NHS Trust.

    Mr Andrew Horncastle

    Andrew is a Trustee of the charity and provides vital input to the project with his expertise in dealing with the construction industry